Why the study?
Does ramipril improve outcomes in patients with hypertension, heart failure, nephropathy, or high cardiovascular risk?
Does ramipril improve outcomes in patients with hypertension, heart failure, nephropathy, or high cardiovascular risk?
This review summarizes the evidence supporting the use of ramipril across multiple cardiovascular and renal indications, including its role in preventing cardiovascular events in high-risk patients.
Supports established ramipril indications; leaves open comparative effectiveness versus newer agents.
SUMMARY Ramipril is a long‐acting, lipophylic angiotensin converting enzyme inhibitor. its principle action is to inhibit the conversion of angiotensin I to the active angiotensin II. Ramipril is indicated in the treatment of hypertension, congestive cardiac failure (including that following acute myocardial infarction), nephropathy (with and without diabetes mellitus) and now, following the findings of the HOPE study, in the prevention of cardiovascular events (including myocardial infarction) in high risk individuals. This article concentrates on reviewing the evidence supporting ramipril's use in these indications. (Int J Clin Pract 2000; 54(4): 255‐260)
No takes yet. Share an insight, caveat, or question.
Smith et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: